RxDoctor Payments Data

Marjorie Bisenius, DO

Family Medicine · Omaha, NENPI 1992731574

Payments from drug & device makers

$4,718in general payments, 2019–2025

Across 289 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$653
  • AstraZeneca$430
  • Amgen$303
  • Lilly USA, LLC$263
  • Otsuka America Pharmaceutical, Inc.$185
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$4,712100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,718 in reported general payments places this provider in the 85th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$223,370
Medicare patients
590
Services billed
3,482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$116,961
MounjaroTirzepatide90$104,625
EliquisApixaban45$43,682
JardianceEmpagliflozin52$43,579
RybelsusSemaglutide21$39,796
TrulicityDulaglutide30$27,631
LinzessLinaclotide17$14,890
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,289
Breo ElliptaFluticasone/Vilanterol26$12,755
FarxigaDapagliflozin Propanediol17$9,972
Combivent RespimatIpratropium/Albuterol Sulfate12$5,872
DuleraMometasone/Formoterol14$4,682
PremarinEstrogens, Conjugated12$3,241
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$2,463
Atorvastatin Calcium335$2,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$653$156,757111 claims
Lilly USA, LLCMounjaro, Trulicity$263$132,257120 claims
Boehringer IngelheimJardiance, Combivent Respimat$44$49,45264 claims
PfizerEliquis, Premarin$118$46,92357 claims
GSKTrelegy Ellipta, Breo Ellipta$37$26,04446 claims
AbbVieLinzess, Synthroid$1,133$16,93041 claims
AstraZenecaFarxiga$430$9,97217 claims
MerckDulera$156$4,68214 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$1,823280 claims
Almatica Pharma LLCSertraline Hcl$16$86892 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →